Details for Patent: 8,809,265

Title:	Methods for treating HCV
Abstract:	The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Inventor(s):	Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Gurnee, IL), Cohen; Daniel E. (Wilmette, IL), Podsadecki; Thomas J. (Chicago, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Filing Date:	Oct 19, 2012
Application Number:	13/656,012
Claims:	1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient, wherein said treatment lasts for 8 weeks and does not include administration of either interferon or ribavirin to said patient, and said at least two DAAs comprise PSI-7977 and an HCV NS5A inhibitor, and wherein said patient is a treatment-naive patient infected with HCV genotype 1. 2. The method of claim 1, wherein said HCV NS5A inhibitor is Compound 4 ##STR00011## 3. The method of claim 1, wherein said PSI-7977 is administered at a dose of 400 mg once daily. 4. The method of claim 1, wherein said PSI-7977 and said HCV NS5A inhibitor are co-formulated in a single composition and administered once daily. 5. A method of treatment for HCV, comprising administering at least two DAAs to a patient infected with HCV genotype 1, wherein said treatment lasts for 6 or 7 weeks and does not include administration of either interferon or ribavirin to said patient, and said at least two DAAs comprise PSI-7977, an HCV NS5A inhibitor and another DAA. 6. The method of claim 5, wherein said another DAA is Compound 1 ##STR00012## and said HCV NS5A inhibitor is Compound 4 ##STR00013## 7. The method of claim 5, wherein said PSI-7977 is administered at a dose of 400 mg once daily. 8. The method of claim 5, wherein said another DAA is an HCV protease inhibitor. 9. The method of claim 5, wherein said another DAA is an HCV polymerase inhibitor. 10. The method of claim 5, wherein said patient is a treatment naive patient. 11. The method of claim 5, wherein said patient is an interferon non-responder.